0001104659-26-034951
SEC filingQuoin Pharmaceuticals Ltd. announced Q4 and full-year 2025 financial results with net loss of $4.3 million and $15.8 million respectively, cash position of $18.7 million funding into 2027, closed $104.5 million private placement financing, and key regulatory progress for QRX003 including Orphan Drug and Fast Track Designations for Netherton Syndrome.